Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006

Int J Clin Pharmacol Ther. 2003 Dec;41(12):616-7. doi: 10.5414/cpp41616.
No abstract available

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzenesulfonates / adverse effects*
  • Benzenesulfonates / pharmacology*
  • Carcinoma / pathology*
  • Cell Cycle / drug effects*
  • Colonic Neoplasms / pathology*
  • Humans
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Proto-Oncogene Proteins c-raf / antagonists & inhibitors
  • Pyridines / adverse effects*
  • Pyridines / pharmacology*
  • Sorafenib
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib
  • Proto-Oncogene Proteins c-raf